Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
To explore the efficacy of radiotherapy plus toripalimab Versus standard treatment of
sorafenib in advanced hepatocellular carcinoma with Portal Vein/Hepatic vein Tumor
Thrombosis.